AstraZeneca accelerates drug discovery and clinical insights with AI

AstraZeneca, a global pharmaceutical leader, uses advanced AI and generative AI models on Microsoft Azure to fast-track drug discovery and development at its R&D center in India. Leveraging AI-driven models for protein folding, structure-guided drug design, and antibody discovery, the company improves disease understanding, medicinal target identification, and clinical prediction accuracy. AI and ML tools extract insights from large clinical trial datasets and safety/efficacy analytics, while federated learning enables collaborative model improvement across distributed data sources without compromising privacy. The Azure infrastructure supports intensive compute needs, helping AstraZeneca reduce discovery timelines and increase success rates for new medicines, ultimately driving innovation in the pharma sector.